Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) is a biotechnology company headquartered in San Diego, California, focused on developing and commercializing innovative medicines for central nervous system disorders. The company is a leader in neuropsychiatric drug development, with its flagship product Nuplazid (pimavanserin) approved for Parkinson's disease psychosis[1].
Founded in 1997, Acadia has built expertise in serotonin receptor pharmacology and has expanded into multiple CNS indications including Alzheimer's disease psychosis, schizophrenia, and major depressive disorder[2].
| Program | Target/Mechanism | Indication | Phase | Status |
|---|---|---|---|---|
| Nuplazid (pimavanserin) | 5-HT2A inverse agonist | Parkinson's Disease Psychosis | Approved | Commercial |
| Pimavanserin | 5-HT2A inverse agonist | Alzheimer's Disease Psychosis | Phase 3 | Active |
| ACP-171 | Orexin-2 receptor agonist | Parkinson's Disease | Phase 2 | Active |
| ACP-204 | 5-HT2A inverse agonist | Schizophrenia | Phase 1 | Active |
| ACP-319 | Undisclosed | CNS disorder | Discovery | Research |
Pimavanserin (brand name Nuplazid) is a selective serotonin 5-HT2A inverse agonist approved by the FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). It represents the first and only approved treatment specifically for PDP[3].
Mechanism of Action:
Clinical Benefits:
Approval History:
ACP-171 is a novel orexin-2 receptor agonist being developed for Parkinson's disease. Orexin-2 receptors play a critical role in wakefulness, and their dysfunction contributes to excessive daytime sleepiness and REM sleep behavior disorder in PD[4].
Mechanism:
Development:
ACP-204 is a next-generation 5-HT2A inverse agonist in Phase 1 development for schizophrenia and potentially other CNS disorders[5].
Features:
Acadia is developing pimavanserin for Alzheimer's disease psychosis (ADP), a significant unmet need affecting approximately 40-50% of AD patients[6].
Phase 3 Program (SERENITY):
Rationale:
Acadia is leveraging its CNS expertise to explore new therapeutic approaches:
| Program | Target | Indication |
|---|---|---|
| Undisclosed | 5-HT receptors | Mood disorders |
| Undisclosed | Orexin system | Sleep disorders |
| Undisclosed | Novel targets | Neurodegeneration |
Acadia maintains significant CNS clinical development capabilities:
| Partner | Focus Area | Status |
|---|---|---|
| St. Jude Children's Hospital | Research collaboration | Active |
| Academic institutions | Clinical development | Multiple |
| CRO partners | Trial operations | Active |
Parkinson's Disease Treatment
Serotonin Signaling
Sleep Disorders
Neurocrine Biosciences
Cerevel Therapeutics